JP Patent

JP6034316B2 — Ｐｃｓｋ９遺伝子の発現を阻害するための組成物および方法

Assigned to Alnylam Pharmaceuticals Inc · Expires 2016-11-30 · 9y expired

What this patent protects

Patent listed against inclisiran-sodium.

Drugs covered by this patent

inclisiran-sodium (INCLISIRAN SODIUM)

Patent Metadata

Patent number: JP6034316B2
Jurisdiction: JP
Classification: —
Expires: 2016-11-30
Drug substance claim: No
Drug product claim: No
Assignee: Alnylam Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.